


## LIMK1 inhibitor BMS-4

Cat. No.:	HY-128062		
CAS No.:	905298-84-2		
Molecular Formula:	C <sub>23</sub> H <sub>23</sub> N <sub>7</sub> O <sub>2</sub> S		
Molecular Weight:	461.54		
Target:	LIM Kinase (LIMK)		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	LIMK1 inhibitor BMS-4 is a LIM Kinase (LIMK) inhibitor targeting to LIMK1/2. LIMK1 inhibitor BMS-4 inhibits phosphorylation of cofilin, the LIMK substrate. However, LIMK1 inhibitor BMS-4 is noncytotoxic on A549 cells <sup>[1][2]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	LIMK1 7.25 (pIC <sub>50</sub> )	LIMK2 6.87 (pIC <sub>50</sub> )	
<b>In Vitro</b>	LIMK1 inhibitor BMS-4 (compound 4) (0.014-10 μM; 24 h) inhibits LIMKs in vitro without affecting A549 cell survival or proliferation <sup>[1]</sup> . LIMK1 inhibitor BMS-4 (0.014-1 μM; 2 h) inhibits phosphorylation of the LIMK substrate cofilin in A549 human lung cancer cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

### REFERENCES

- [1]. Collins R, et al. Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity. *J Med Chem.* 2022 Oct 27;65(20):13705-13713.
- [2]. Ross-Macdonald P, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. *Mol Cancer Ther.* 2008 Nov;7(11):3490-8.
- [3]. Collins R, et al. Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity. *J Med Chem.* 2022 Oct 27;65(20):13705-13713.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA